Meta Analysis of Infection Status of Women After Vaccination with Human Papillomavirus Vaccine
School of Basic Medical Science, North China University of Science and Technology, Tangshan 063210, China
| Abstract: | Objective: To analyze the infection status of human papillomavirus (HPV) in women after vaccination by meta-analysis. Methods: The PubMed, Wiley, science direct and web of science databases were searched by computer. The full-text English literatures published since the establishment of the database were collected with HPV and vaccination as key words. The literatures that met the inclusion criteria were selected and used RevMan5.3 analysis. Results: Nine literatures were included, and the number of researchers was 60570. The results showed that the protective effect of HPV16/18 and HPV31/33/45/52/58 related 6-month persistent infection in vaccinated women was higher than that in non vaccinated women, and the protective rate was 95% (RR: 0.05, 95% CI: 0.04 ~ 0.06). The protective effect of 12-month persistent infection related to any type of HPV in the experimental group was higher than that in the control group, and the protective rate was 96% (RR: 0.04, 95% CI: 0.03 ~ 0.06). The incidence of CIN1+ associated with HPV16/18 and (or) HPV6/11/16/18 decreased in women after vaccination in a protocol compliant population (PPE) (RR: 0.12, 95% CI: 0.06 ~ 0.22); The incidence rate of CIN2+ was lower than that of non vaccinated population (RR: 0.06, 95% CI: 0.02 ~ 0.18). The incidence of CIN1+ associated with HPV16/18 and (or) HPV6/11/16/18 in vaccinated women was lower than that in non vaccinated people in the modified intention to analyze population (mITT) (RR: 0.15, 95% CI: 0.07 ~ 0.31). The incidence rate of CIN2+ was lower than that of non vaccinated population (RR: 0.11, 95% CI: 0.04 ~ 0.34). The incidence of HPV6/11/16/18/31/33/45/52/58 related cervical lesions was lower than that of the control group, and the final combined effect value was RR = 0.02 (95% CI: 0.01 ~ 0.04). The incidence rate of hpv6/11/16/18/31/33/45/52/58 related vaginal and vulvar diseases of any grade and high grade was lower than that of the control group, and the final combined effect value was RR=0.06 (95% CI: 0.03 ~ 0.10). Conclusion: The protective effect of HPV vaccine against persistent HPV infection in women is higher, and the incidence rate of related cervical, vaginal and vulvar diseases is lower. Bivalent, tetravalent and ninvalent vaccines all show long-term protection. |
| Keywords: | Meta Analysis; HPV Infection; Vaccination |
| DOI: | 10.57237/j.life.2023.04.004 |
View:
Downloads:
Received: 31 May 2023
Accepted: 3 August 2023
Published Online: 27 December 2023
Funding
| 1. | 河北省自然基金中医药联合基金培育项目 (编号: H202209048) |
References
| [1] | SZYMONOWICZ K A, CHEN J. Biological and clinical aspects of HPV-related cancers [J]. Cancer biology & medicine, 2020, 17(4): 864-878. |
| [2] | 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识 [J]. 中华预防医学杂志, 2019, 53(8): 761-803. |
| [3] | JOURA E A, GIULIANO A R, IVERSEN O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women [J]. The New England journal of medicine, 2015, 372(8): 711-723. |
| [4] | 陈汶. 人乳头瘤病毒疫苗安全性研究的新进展 [J]. 中华预防医学杂志, 2021, 55(03): 428-434. |
| [5] | 周旭, 岳雅清, 贾荣霞, 等. 预防性人乳头瘤病毒疫苗免疫接种研究进展 [J]. 中华实验和临床病毒学杂志, 2020, 34(05): 567-572. |
| [6] | 杨旭梅, 金蓉蓉, 周慧玲, 等. HPV疫苗研究进展及推广接种过程中的影响因素 [J]. 中华临床医师杂志(电子版), 2021, 15(03): 218-223. |
| [7] | WHEELER C M, SKINNER S R, DEL ROSARIO-RAYMUNDO M R, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J]. The Lancet Infectious Diseases, 2016, 16(10): 1154-1168. |
| [8] | HUH W K, JOURA E A, GIULIANO A R, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial [J]. Lancet (London, England), 2017, 390(10108): 2143-2159. |
| [9] | RUIZ-STERNBERG Á M, MOREIRA E D, RESTREPO J A, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women [J]. Papillomavirus research (Amsterdam, Netherlands), 2018, 5: 63-74. |
| [10] | GARLAND S M, PITISUTTITHUM P, NGAN H Y S, et al. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries [J]. The Journal of infectious diseases, 2018, 218(1): 95-108. |
| [11] | GIULIANO A R, JOURA E A, GARLAND S M, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population [J]. Gynecologic oncology, 2019, 154(1): 110-117. |
| [12] | WEI L, XIE X, LIU J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up [J]. Vaccine, 2019, 37(27): 3617-3624. |
| [13] | ZHU F-C, HU S-Y, HONG Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial [J]. Cancer medicine, 2019, 8(14): 6195-6211. |
| [14] | QIAO Y-L, WU T, LI R-C, et al. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial [J]. Journal of the National Cancer Institute, 2020, 112(2): 145-153. |
| [15] | PORRAS C, TSANG S H, HERRERO R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial [J]. The Lancet Oncology, 2020, 21(12): 1643-1652. |
| [16] | 杨丽, 王静, 马彩玲. 预防性HPV疫苗预防宫颈癌有效性和安全性Meta分析 [J]. 中华肿瘤防治杂志, 2015, 22(09): 719-727. |
| [17] | HARPER D M, NIEMINEN P, DONDERS G, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up [J]. Gynecologic oncology, 2019, 153(3): 521-529. |
| [18] | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2018, 68(6): 394-424. |
| [19] | BRUNI L, DIAZ M, BARRIONUEVO-ROSAS L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis [J]. The Lancet Global health, 2016, 4(7): e453-463. |
| [20] | PETROSKY E, BOCCHINI J A, HARIRI S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices [J]. MMWR Morbidity and mortality weekly report, 2015, 64(11): 300-304. |
| [21] | GUEVARA A, CABELLO R, WOELBER L, et al. Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine [J]. Vaccine, 2017, 35(37): 5050-5057. |
| [22] | KJAER S K, NYGåRD M, DILLNER J, et al. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries [J]. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2018, 66(3): 339-345. |
| [23] | 张继红, 腾国伟, 斗智, 等. 九价人乳头瘤病毒疫苗接种后保护效果、免疫原性及安全性meta分析 [J]. 中国公共卫生, 2019, 35(04): 491-496. |
| [24] | VILLA L L, COSTA R L R, PETTA C A, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial [J]. The Lancet Oncology, 2005, 6(5): 271-278. |
| [25] | PAAVONEN J, JENKINS D, BOSCH F X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial [J]. Lancet (London, England), 2007, 369(9580): 2161-2170. |
| [26] | SKINNER S R, SZAREWSKI A, ROMANOWSKI B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study [J]. Lancet (London, England), 2014, 384(9961): 2213-2227. |
| [27] | 滕秋丽, 牛茂源, 刘玉莹, 等. HPV感染对男性的危害与HPV疫苗接种对男性的保护 [J]. 中国免疫学杂志, 2022, 38(04): 507-514. |
| [28] | 赵爽, 赵方辉. HPV治疗性疫苗研究进展 [J]. 中华预防医学杂志, 2018, 52(05): 556-560. |
| [29] | BONJOUR M, CHARVAT H, FRANCO E L, et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis [J]. The Lancet Public health, 2021, 6(7): e510-e521. |
| [30] | 庞晓庆, 郝敏, 赵卫红, 等. 宫颈上皮内瘤变管理的进展[J]. 肿瘤学杂志, 2014, 20(03): 181-185. |
| [31] | KJAER S K, NYGåRD M, SUNDSTRöM K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries [J]. EClinicalMedicine, 2020, 23: 100401. |
| [32] | GOLDSTONE S E, GIULIANO A R, PALEFSKY J M, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial [J]. The Lancet Infectious diseases, 2022, 22(3): 413-425. |
| [33] | MIKAMO H, YAMAGISHI Y, MURATA S, et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study [J]. Vaccine, 2019, 37(12): 1651-1658. |
| [34] | 李广, 秦逸飞, 黄莉声, 等. 九价HPV疫苗安全性的meta分析 [J]. 现代妇产科进展, 2018, 27(12): 905-909. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us